Where do we stand with targeted therapy of refractory thyroid cancer?--Utility of RECIST criteria
- PMID: 18341374
- DOI: 10.1089/thy.2008.0038
Where do we stand with targeted therapy of refractory thyroid cancer?--Utility of RECIST criteria
Comment on
-
A phase II study of gefitinib in patients with advanced thyroid cancer.Thyroid. 2008 Mar;18(3):317-23. doi: 10.1089/thy.2007.0120. Thyroid. 2008. PMID: 17985985 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
